Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck KGaA

Latest From Merck KGaA

Late-Breakers To Look Out For At ASCO 2020

ASCO 2020, which takes place from 29-31 May, will necessarily depart from its predecessors in location, content and delivery. Here, with input from Biomedtracker and Datamonitor Healthcare, we take a look at what can be expected during this year’s late-breaking clinical trial sessions.

ASCO Companies

COVID-19 Hits Merck KGaA's MS Drug Mavenclad

The lockdowns caused by coronavirus has led to significant decline of multiple sclerosis patients getting to see neurologists and getting treatment. It has also reduced the number of treatment switches and Merck's drug Mavenclad is suffering as a consequence.

Sales & Earnings Coronavirus COVID-19

GSK Cancer R&D Chief Sees Three Key Approvals In Q2

GlaxoSmithKline expects regulatory approval for three key cancer products by the middle of this year, anchoring it as a leading oncology company, Axel Hoos tells Scrip.

Approvals Commercial

Newron STARS Fade With Sarizotan Failure

Sarizotan, licensed from Merck KGaA in 2011 for Rett syndrome, was seen as a potential gamechanger for Newron but the termination of the project leaves a huge hole in the Italian group's pipeline.

Rare Diseases Clinical Trials
See All

Company Information